Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001300324 | SCV001489461 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2021-01-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with ALK-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces histidine with tyrosine at codon 258 of the ALK protein (p.His258Tyr). The histidine residue is moderately conserved and there is a moderate physicochemical difference between histidine and tyrosine. |
| Ambry Genetics | RCV002402835 | SCV002674541 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-05-30 | criteria provided, single submitter | clinical testing | The p.H258Y variant (also known as c.772C>T), located in coding exon 2 of the ALK gene, results from a C to T substitution at nucleotide position 772. The histidine at codon 258 is replaced by tyrosine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |